NYRADA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.092 AUD | -2.13% |
|
-6.12% | +318.18% |
| Apr. 30 | Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury | MT |
| Apr. 18 | Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024 |
Presenter SpeechJonathan Jackson (Attendees)Nyrada's CEO, James Bonnar; and Chair of Scientifi...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Nyrada Inc. is a preclinical stage, drug development company specializing in small molecule drugs to treat cardiovascular and neurological diseases. The Companyâs two lead programs are focused on cholesterol-lowering and brain injury. These programs are developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury (TBI). Its Cholesterol-Lowering Program is an oral PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs. Its Brain Injury Program is developing a drug to block secondary brain damage that occurs following a stroke or TBI, such as severe head trauma from contact sports, a fall, or a motor vehicle accident. The Brain Injury Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischemic stroke. It is also developing new therapies.
Sector
Pharmaceuticals
Calendar
2024-05-15
- Extraordinary Shareholders Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +318.18% | 10.95M | |
| +34.00% | 704B | |
| +26.90% | 577B | |
| -7.75% | 348B | |
| +18.53% | 327B | |
| +4.95% | 288B | |
| +14.85% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -4.89% | 147B |
- Stock Market
- Equities
- NYR Stock
- News Nyrada Inc.
- Transcript : Nyrada Inc. - Special Call
